Document is current
Any future updates will be listed below
-
Authors
Plasencia, Christina
Eschle, Jonas
Hatz, Katja
-
Funding
Funding for this research was provided by:
University of Basel
- License Information
-
More Information
Article History
Received: 20 May 2025
Accepted: 24 July 2025
First Online: 14 August 2025
Declarations
:
: All included patients gave general written informed consent or were included in the assumption of their consent to avoid attrition-bias if obtaining general consent was disproportionate or impossible, as those patients were no longer being treated at our clinic at the time of the analysis, as approved by the local ethics committee (Kantonale Ethics Committee Northwestern Switzerland, EKNZ, EKNZ No 2019–00752). Thereby agreeing for their use of health-related personal data for research purposes. This study was conducted according to the Declaration of Helsinki of the World Medical Association in accordance with the Good Clinical Practice Guidelines of the International Conference on Harmonisation (ICH).
: Not applicable.
: KH: Advisory board participant and lecturer for Apellis, Bayer, Roche, Abbvie/Allergan, Novartis; contract research and/or grant support for Bayer, Roche, Abbvie/Allergan, Novartis. No financial disclosures by all other authors.
